Evaluation of Cefuroxime Axetil and Cefadroxil Suspensions
|
|
- Bartholomew Scott
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1992, p /92/ $02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 8 Evaluation of Cefuroxime Axetil and Suspensions for Treatment of Pediatric Skin Infections RICHARD F. JACOBS,`* WALLACE D. BROWN,2 STEPHEN CHARTRAND,3 PAUL DARDEN,4 MARGARET A. DREHOBL,S ROBERT YETMAN,6 AND MICHAEL J. OSSI7 Arkansas Children's Hospital, Little Rock, Arkansas ; Raleigh Pediatric Association, Raleigh, North Carolina ; Creighton University School of Medicine, Omaha, Nebraska ; Medical University of South Carolina, Charleston, South Carolina ; Scripps Clinic-Rancho Bernardo, San Diego, California ; University of Te-xas Medical School, Houston, Texas ; and Glaxo Inc., Research Triangle Park, North Carolina Received 7 October 1991/Accepted 15 May 1992 A randomized, single-blind, multicenter study was conducted to evaluate the safety and efficacy of cefuroxime and cefadroxil suspensions for the treatment of skin or skin structure infections in 287 children. Each drug was given at a dosage of 30 mg/kg of body weight per day in two divided doses. Staphylococcus aureus and Streptococcus pyogenes, or a combination of the two, were the primary pathogens isolated from infected skin lesions. A satisfactory bacteriological response (cure or presumed cure) was obtained in 97.1 and 94.3% of children in the cefuroxime and cefadroxil groups, respectively (P > 0.05). Satisfactory clinical responses (cure or improvement) were more likely to occur in cefuroxime recipients than in cefadroxil recipients (97.8 versus 90.3%; P < 0.05). Both regimens were equally well tolerated, with adverse events occurring in 7.9 and 6.1% of cefuroxime and cefadroxil recipients, respectively. There were more patients who refused to take cefuroxime (7 of 189) than there were who refused to take cefadroxil (0 of 98), but the difference was not statistically significant (P = 0.1). In this study, cefuroxime was at least as effective as cefadroxil in resolving skin and skin structure infections in children. Cefuroxime is an expanded-spectrum cephalosporin with improved P-lactamase stability and a broad spectrum of activity against clinically important gram-positive and gramnegative pathogens. The lowest concentrations that inhibited the growth of 90% of the Staphylococcus aureus and Streptococcus pyogenes strains tested are 1 to 2 and <0.125,ug/ml, respectively (2). Cefuroxime, the acetyloxyethyl ester of cefuroxime, is a prodrug that is suitable for oral administration. After oral ingestion, cefuroxime is deesterified in the intestinal mucosa and appears as cefuroxime in the blood. Peak concentrations in serum increase in proportion to dose and are 3.3 and 5.1,ug/ml after oral doses of a cefuroxime suspension of 10 and 15 mg/kg of body weight, respectively (12). These results are comparable to those achieved in adults following administration of a 250-mg cefuroxime tablet (7). Thus, achievable concentrations in serum exceed the MICs for common cutaneous pathogens (2). The tablet formulation of cefuroxime has previously been found to be effective in the treatment of skin or skin structure infections in adults (4, 5). The purpose of the study described here was to evaluate the efficacy and safety of a new liquid suspension of cefuroxime in children with skin or skin structure infections. suspension was selected as the active control because it has been proven to be effective in the treatment of skin or skin structure infections and is suitable for twice-daily administration. * Corresponding author MATERIALS AND METHODS Eligibility criteria. Children (ages 3 months to 12 years) with skin or skin structure infections requiring antibiotic treatment were eligible to participate in the study. Patients were excluded if any of the following were present: infection requiring incision and drainage, hypersensitivity to cephalosporin or penicillin, previous systemic antibacterial drug treatment (within 7 days), history of gastrointestinal disorder that could alter drug absorption (within 3 months), unstable concomitant disease, immunosuppression, or previous enrollment in this study. Patients were to be withdrawn after enrollment if, upon culture and susceptibility testing, no pathogen was isolated or the pathogen was not susceptible to the study drugs (e.g., methicillin-resistant S. aureus). Patients were discontinued from the study if any of the following occurred: adverse event necessitating discontinuation of drug therapy, treatment failure or recurrence of infection, patient refusal of further doses, or failure to return for follow-up. Study design. This was an evaluator-blinded, multicenter study. Patients were randomly chosen to receive either cefuroxime suspension (Ceftin; Glaxo Inc., Research Triangle Park, N.C.) or cefadroxil suspension (Duricef; Mead Johnson Pharmaceuticals, Evansville, Ind.) in a 2:1 ratio according to a predetermined randomization schedule. Both drugs were administered orally at a dosage of 30 mg/kg/day in two divided doses every 12 h (maximum dose, 1 g/day) for 10 days. Cefuroxime was given after morning and evening meals, because postprandial administration of cefuroxime (in the tablet form) has been shown to enhance absorption (3). was given without regard to mealtimes, as recommended by the manufacturer. Compliance was assessed by assay of antibiotic activity in urine during treatment and by the volume of drug
2 VOL. 36, 1992 CEFUROXIME AXETIL AND CEFADROXIL SUSPENSION EVALUATION 1615 returned upon completion of the treatment period. The absence of detectable antibacterial activity in a duringtreatment urine sample excluded a patient from the efficacy analyses. Written informed consent was obtained from all patients' parents or legal guardians. This protocol was approved by the institutional review boards of the respective investigators' institutions. Efficacy assessment. Response to treatment was assessed bacteriologically and clinically. Although 10 days is the standard length of therapy for most infections in children, for purposes of efficacy assessments, 5 days (10 doses) was predetermined as the minimum length of treatment necessary to effect clinical improvement and eradication of the causative organism(s) from superficial skin infections. Specimens from the involved skin lesion(s) were obtained for bacterial culture and susceptibility testing at the initial visit and, if culturable material was present, at the duringand posttreatment visits. Material for culture was obtained by needle aspiration or sterile swab of a lesion(s). Crusted material was partially unroofed. The culture material obtained was processed at an accredited laboratory according to that laboratory's standard protocol for wound or surface specimen culture. Standard disk or dilution methods were used for susceptibility testing; the current criteria of the National Committee for Clinical Laboratory Standards were used to interpret the results (10). Bacteriological outcome was determined at the completion of the study or when the patient's condition dictated the need for alternate antibiotic therapy. Bacterial responses were rated as cure (initial pathogen eradicated), failure (identification of the original pathogen in a follow-up culture), or relapse (eradication with subsequent isolation of the original pathogen). Presumptive bacterial responses were made on the basis of the clinical response when follow-up cultures were not obtainable because of healing of the lesion(s) (e.g., presumed cure). For statistical analysis, bacteriological outcomes were grouped as satisfactory (cure or presumed cure) or unsatisfactory (failure or relapse). Patients underwent at least three clinical evaluations at the following intervals: at the start of therapy (initial visit), at 4 to 6 days after the initiation of therapy (during treatment), and at 5 to 7 days after the completion of therapy (posttreatment). If complete healing did not occur at 5 to 7 days, an additional visit was required at 14 to 20 days posttreatment. Clinical response was rated as cure (resolution of clinical signs and symptoms of infection), improvement (resolution of signs and symptoms with incomplete lesion healing; further antibacterial therapy required), failure (no improvement after 25 days of treatment or discontinuation of treatment because of adverse event; alternate antibacterial therapy required), or recurrence (initial diminution of signs and symptoms but recurrence by the posttreatment visit; further or alternate antibacterial therapy required). For statistical analysis, a satisfactory clinical response was defined as cure or improvement; an unsatisfactory clinical response was defined as failure or recurrence. Safety assessment. All patients were monitored for adverse events. Each patient's parent or guardian was interviewed at each visit to determine the presence of adverse events. In order to avoid bias in eliciting adverse events, the initial questioning was restricted to "Is your child having any problems?" In addition, physical findings that were detected by the physician observer but that were not present at the initial visit were recorded as adverse events and were assessed as to their possible relationship to treatment. For the purpose of monitoring laboratory safety, blood was TABLE 1. Parameter Patient enrollment and demographic dataa Cefuroxime Enrollment data Total enrolled (no.) Population for analysis 156 (82.5) 82 (83.7) (no. [%]) P value Age (mo)b ± 4.8 NSc Wt (kg)b 25.2 ± ± 1.6 NS No. (%) of females 72 (46.2) 39 (47.6) NS Ethnic origin (no. [%]) Caucasian 71 (45.5) 48 (58.5) Black 74 (47.4) 26 (31.7) Hispanic 9 (5.8) 7 (8.5) Other 2 (1.3) 1 (1.2) Diagnosisd Impetigo 126 (80.8) 66 (80.5) NS Cellulitis 14 (9.0) 8 (9.8) Injury-induced wound 13 (8.3) 6 (7.3) Paronychia 10 (6.4) 4 (4.9) Other' 7 (4.5) 5 (6.1) Therapy Mean dose (mg/kg/day)b 28.6 ± ± 0.4 NS Mean duration (days) 10.3 ± ± 0.2 NS a Demographic data of the population used for analysis. b Data are means ± standard errors. c NS, not significant. d There was more than one primary diagnosis for some patients. Other diagnoses were furunculosis (for the cefuroxime and cefadroxil treatment groups, 2 and 0 patients, respectively), pyoderma (1 and 3 patients, respectively), carbunculosis (1 and 0 patients, respectively), buttock abscess (1 and 0 patients, respectively), folliculitis (1 and 0 patients, respectively), skin infection began as contact dermatitis (1 and 0 patients, respectively), lymphangitis (0 and 1 patient, respectively), and nonspecific skin rash with exudates (0 and 1 patient, respectively). collected for complete blood count with differential, platelet count, prothrombin time, and the direct Coomb's test and for evaluation of hepatic enzymes, blood urea nitrogen, and serum creatinine. Urine was obtained for evaluation of albumin and glucose and a microscopic examination. These tests were performed at the initial and posttreatment visits. Statistical analysis. Two-sided statistical tests were used. Demographic data were summarized by using a van Elteren statistic (13) (patient age and weight), a Mantel-Haenszel statistic (9) controlling for investigational center (sex and ethnic origin), or a Fisher exact test (8) (allergy, significant medical history, and abnormal physical finding) to examine the comparabilities of treatment groups. Summary statistics were performed on bacteriological and clinical assessments; the Mantel-Haenszel test was used to evaluate differences between treatment groups. The incidence rates of adverse events were compared between treatment groups by using a Fisher exact test. A P value of 0.05 or less was considered statistically significant. RESULTS A total of 287 patients from 11 centers were enrolled in the study (Table 1). Forty-nine patients were excluded from the analyses because of the following prespecified protocol violations: inability to isolate a pathogen from the pretreat-
3 1616 JACOBS ET AL. ment culture (for the cefuroxime and cefadroxil treatment groups, 17 and 10 patients, respectively), negative urine bioassay (8 and 1 patient, respectively), absence of susceptibility testing on pretreatment pathogen (6 and 4 patients, respectively), resistant pathogen (2 and 0 patients, respectively), and concurrent antimicrobial therapy (0 and 1 patient, respectively). The two resistant pathogens were methicillin-resistant S. aureus. One cefuroxime treated patient from whom no pathogen was isolated in the pretreatment culture was withdrawn from the study because of the patient's refusal to take the study medication. Two additional patients who were withdrawn from the study because of refusal to take the study medication were excluded from the analysis because of prior negative urine bioassays. The remaining six patients with negative urine bioassays were either lost to follow-up (n = 3) or completed the study but did not return medication bottles to provide other evidence of compliance (n = 3). The cefadroxil-treated patient completed the study but did not return medication bottles to provide other evidence of compliance. In total, three cefuroxime -treated patients who refused to take the study medication were excluded from analysis because of the prespecified protocol violations described above; data for these patients are not given below in the bacteriological and clinical outcome sections. All patients with protocol violations were included in an intent-to-treat analysis, the results of which appear later in this report. There were no differences (P > 0.05) between the two treatment groups in the proportion of patients with any particular reason for exclusion from analysis. After excluding the 49 patients, 156 patients in the cefuroxime treatment group and 82 patients in the cefadroxil treatment group were available for bacteriological and clinical efficacy analyses. These remaining patients were evenly distributed on the basis of age, weight, and sex but not ethnic origin. The majority of cefadroxil recipients were Caucasian, whereas cefuroxime recipients were nearly evenly divided between Caucasian and black ethnic origins (P < 0.007). The primary diagnosis in both groups was impetigo; this was followed in descending order of frequency by cellulitis, injury-induced wound infection, and paronychia. The mean dose received (approximately 28 mg/kg/day) and the duration of treatment (10 days) were nearly identical for the two treatment groups. Bacteriological outcome. In the cefuroxime -treated patients, 198 of 206 pathogens isolated were either S. aureus (n = 129; 63%) or S. pyogenes (n = 69; 33%). Both S. aureus and S. pyogenes were isolated as copathogens from 47 of 156 patients in this group. In the cefadroxil group, 104 of 110 pathogens were S. aureus (71; 65%) or S. pyogenes (33; 30%). Both microorganisms were isolated from 23 of 82 patients in this group. Thirty patients were bacteriologically unevaluable because of failure to return for follow-up, drug treatment for less than 5 days (less than 10 doses), or clinical recurrence without a documented bacteriological outcome (Table 2). Of the seven cefuroxime -treated patients classified by the investigator as receiving less than 5 days of study drug, four withdrew from the study because of refusal to take the study medication, one withdrew before any doses were given, and two withdrew because of an inability to complete the study requirements for personal reasons. Of the cefadroxil-treated patients who received less than 5 days of study drug, one withdrew for personal reasons and one withdrew because of an adverse event. Of the remaining patients, satisfactory responses occurred in 97.1 and 94.3% of cefuroxime TABLE 2. Bacteriological outcome a Result Cefuroxime Cefadrox Satisfactory 134 (97.1) 66 (94.3)b Cure 27 (19.6) 12 (17.1) Presumed cure 107 (77.5) 54 (77.1) Unsatisfactory 4 (2.9) 4 (5.7) Failure 3 (2.2) 4 (5.7) Relapse 1 (0.7) 0 Subtotal (bacteriologically evaluable) Unevaluable Lost to follow-up 11 9 Received drug for <5 days 7 2 Clinical recurrence without 0 1 documented bacteriological outcome Total a Percentage of bacteriologically evaluable patients. b p = 0.242, by comparing satisfactory versus unsatisfactory responses. and cefadroxil recipients, respectively (P = 0.242). In the cefuroxime group, all unsatisfactory responses were associated with infections caused by S. aureus (three failures, one relapse). Likewise, unsatisfactory responses in the cefadroxil group were associated with infections caused by S. aureus (four treatment failures). Two of these patients had polymicrobial infections that were also caused by S. pyogenes or non-group A,,3-hemolytic streptococci. When all patients were included in an intent-to-treat analysis (i.e., patients previously excluded because of prespecified protocol violations and patients classified as bacteriologically unevaluable), a satisfactory response was defined as cure or improvement, and an unsatisfactory response was all other responses (including unevaluable). In these evaluable patients, satisfactory responses occurred in 70.9 and 68.4% of cefuroxime and cefadroxil recipients, respectively (P = 0.625) (Table 3). Clinical outcome. Twenty-eight patients were clinically unevaluable because of failure to return for follow-up, drug treatment for less than 5 days (less than 10 doses), or withdrawal from the study for reasons other than an adverse event (Table 4). Six cefuroxime recipients were classified by the investigator as receiving drug for less than 5 days. These patients were described above in the bacterio- TABLE 3. ANTimICROB. AGENTS CHEMOTHER. Bacteriological outcome (intent to treat) Resulta Cefuroxime Satisfactory 134 (70.9) 67 (68.4)b Unsatisfactory 55 (29.1) 31 (31.6) All patients a Satisfactory was defined as cure, presumed cure, or cure with infection. Unsatisfactory was defined as all other responses (including unevaluable). b p = 0.625, by comparing satisfactory versus unsatisfactory responses.
4 VOL. 36, 1992 CEFUROXIME AXETIL AND CEFADROXIL SUSPENSION EVALUATION 1617 TABLE 4. Clinical outcome a Result Cefuroxime Satisfactory 135 (97.8) 65 (90.3)b Cure 132 (95.7) 65 (90.3) Improvement 3 (2.2) 0 Unsatisfactory 3 (2.2) 7 (9.7) Failure 0 1 (1.4) Recurrence 3 (2.2) 6 (8.3) Subtotal (clinically evaluable) Unevaluable Lost to follow-up 11 8 Received drug for <5 days 6 0 Withdrawal (other than adverse 1 2 event) Total a Percentage of clinically evaluable patients. b P = 0.009, by comparing satisfactory versus unsatisfactory responses. logical outcome section. In addition, the one patient who was unevaluable because of reasons other than an adverse event was the patient who was withdrawn from the study prior to receiving any study drug (classified as receiving drug for less than 5 days in the bacteriological outcome assessment). No cefadroxil-treated patients were classified as clinically unevaluable by the investigator because they had received study drug for less than 5 days. The two patients in this category under bacteriological outcome were considered clinical failures because of an adverse event or were withdrawn from the study for reasons other than an adverse event (i.e., personal reasons). For the remaining patients, satisfactory clinical response rates were higher in cefuroxime than in cefadroxil recipients (97.8 versus 90.3%; P = 0.009). When the patients that were excluded from the "clinical outcome" analysis were reassessed as having unsatisfactory outcomes, i.e., an intent-to-treat analysis, the difference in response rates in favor of cefuroxime (81.5 versus 78.6%) was no longer statistically significant (P = 0.5) (Table 5). This can be explained by the addition of more patients who were previously excluded from the cefuroxime group because of poor compliance. However, 86.7 and 88.8% of cefuroxime and cefadroxil recipients, respectively, completed at least 80% of the prescribed therapies. Resulta TABLE 5. Clinical outcome (intent to treat) Cefuroxime Satisfactory 154 (81.5) 77 (78.6)b Unsatisfactory 35 (18.5) 21 (21.4) All patients a Satisfactory was defined as cure or improved. Unsatisfactory was defined as all other responses (including unevaluable). b p = 0.504, by comparing satisfactory versus unsatisfactory responses. TABLE 6. Adverse events almost certainly, probably, or possibly related to drug therapy Adverse event Cefuroxime (n = 189) (n = 98) Any adverse event 15 (7.9) 6 (6.1) Gastrointestinal disturbance Diarrhea or loose stools 7 (3.7) 1 (1.0) Abdominal pain 2 (1.1) 0 Nausea or vomiting 0 1 (1.0) Subtotal 9 (4.8) 2 (2.0) Skin disturbance Diaper rash 4 (2.1) 3 (3.1) Unspecified rash 1 (0.5) 1 (1.0) Subtotal 5 (2.6) 4 (4.1) Other Hyperactivity 0 1 (1.0) Vaginal irritation 1 (1.1)a 0 Subtotal 1 (0.5) 1 (1.0) Laboratory abnormalities, elevated 1 (0.5) 0 liver enzymes a Calculated as the percentage of female patients. In the evaluable population, after controlling for differences in ethnic origin (Caucasian versus all other ethnic origins) and investigational centers, there was still a significant difference in the clinical responses but there was no difference in the bacteriological responses. Adverse events. In general, adverse events were mild to moderate in severity. One patient discontinued cefuroxime because of diarrhea, which resolved spontaneously without further treatment. One patient discontinued cefadroxil because of a rash, which resolved spontaneously. Adverse events considered by the clinician to be possibly, probably, or almost certainly related to the study drugs occurred in 7.9 and 6.1% of all cefuroxime and cefadroxil recipients, respectively (P = 0.641) (Table 6). The adverse event profiles were similar in both treatment groups and consisted primarily of gastrointestinal disturbances (e.g., diarrhea or loose stools) and diaper rash. Only one patient, a cefuroxime recipient, experienced an abnormal laboratory value, which consisted of an increase in serum glutamic oxalacetic transaminase from 30 U/liter at the initial visit to 48 U/liter at the posttreatment visit and to 52 U/liter 2 weeks later. The patient remained asymptomatic throughout this period of time. The patient's mother refused further testing, and the physician observer thought that the abnormality could be drug related. Otherwise, there were no clinically significant changes in hematologic or chemistry parameters. Drug stop dates showed that study drug was taken for 10 days or more by 153 (81.0%) and 84 (85.7%) of cefuroxime and cefadroxil recipients, respectively. One of the study medications was taken for 8 to 9 days by 11 (5.8%) cefuroxime recipients and 3 (3.1%) cefadroxil recipients. Nine (4.7%) cefuroxime -treated patients and two (2.0%) cefadroxil-treated patients took drug for less than 8 days. Of the nine cefuroxime -treated patients who took drug for less than 8 days, six withdrew from the study because of refusal to take the study medication. In addition, one cefuroxime -treated patient was withdrawn from
5 1618 JACOBS ET AL. the study because of refusal to take the study medication, but the drug stop date was not recorded. In total, seven (3.7%) cefuroxime -treated patients were withdrawn for this reason. The disposition of these patients for analysis was discussed above. No cefadroxil-treated patients withdrew from the study because of refusal to take the study drug. Drug stop dates were not available for 33 patients (16 cefuroxime recipients, 9 cefadroxil recipients), of which 14 (7.4%) cefuroxime recipients and 7 (7.1%) cefadroxil recipients were lost to follow-up. Of the remaining patients, none were withdrawn because of refusal to take study medication. DISCUSSION This is the first comparative study of a new formulation of cefuroxime suitable for oral administration to children with skin or skin structure infections. Clinical (97.1%) and bacteriological (97.8%) response rates in the current study approximated those reported in adults receiving the tablet formulation. The overall clinical improvement rate was 95% in 97 patients who participated in a noncomparative study (5). In a study with a design similar to that of the study described here, cefuroxime in the tablet formulation produced clinical and bacteriological response rates (97 and 96%, respectively) higher than those of cephalexin (89 and 85%, respectively; P < 0.05) and similar to those of cefadroxil (94 and 93%, respectively; P > 0.05) (4). In other comparative studies, the authors concluded that cefuroxime is as effective as amoxicillin-clavulanate (14) and cefaclor (11). In those trials, clinical and bacteriological response rates from 92 to 97% were achieved. In the study described here, bacteriological response rates were comparable to those achieved with the cefadroxil suspension (approximately 97% in each group), but clinical responses were higher in cefuroxime recipients (97.8 versus 90.3%; P = 0.009). The difference between treatment groups did not appear to be due to a spuriously low response rate in the cefadroxil group, because the response rate was consistent with those previously reported in comparative trials of patients with skin or skin structure infections (1, 6). The new cefuroxime suspension was well tolerated in the study described here. The incidence and profile of adverse events of the cefuroxime suspension closely resembled that of the cefadroxil suspension. Only 7.9% of children experienced adverse events during cefuroxime therapy; these adverse events were primarily manifested as gastrointestinal disturbances (e.g., diarrhea or loose stools) or diaper rash. No episodes of nausea or vomiting were reported in the cefuroxime group. In this single-blind, randomized study, a suspension formulation of cefuroxime produced bacteriological response rates comparable to those of the cefadroxil suspension (97.1 versus 94.3%) in children with skin or skin structure infections. The clinical response rate was higher in the cefuroxime group (97.8 versus 90.3%; P < 0.05). ANTimICROB. AGENTS CHEMOTHER. Both regimens were well tolerated. These results indicate that the cefuroxime suspension is safe and efficacious in the treatment of skin and skin structure infections in children. ACKNOWLEDGMENTS We thank Joseph Quinn for performing statistical analyses and Nancy E. Powell for assisting with the execution of this study and preparation of the manuscript. This study was supported by a grant from Glaxo Inc. REFERENCES 1. Ballantyne, F. N Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections. Clin. Ther. 7: Dornbusch, K., G. Kronvall, G. E. Goransson, and E. Mortsell In vitro activity of FCE against respiratory pathogens with reference to production of P-lactamases. J. Antimicrob. Chemother. 23(Suppl. C): Finn, A., A. Straughn, M. Meyer, and J. Chubb Effect of dose and food on the bioavailability of cefuroxime. Biopharm. Drug Dispos. 8: Gooch, W. M., III, L. Kaminester, G. W. Cole, et al Clinical comparison of cefuroxime, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. Dermatologica 183: Gudgeon, A. C., M. J. Vandenburg, L. J. Wight, G. K. Griffiths, and M. Kelsey Is oral cefuroxime suitable for the treatment of unidentified bacterial infection of skin and soft tissue? Br. J. Clin. Pract. 41: Hains, C. S., S. E. Johnson, and K. G. Nelson Once daily cefadroxil therapy for pyoderma. Pediatr. Infect. Dis. J. 8: Harding, S. M., P. E. 0. Williams, and J. Ayrton Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob. Agents Chemother. 25: Kendall, M., and A. Stuart The advanced theory of statistics, vol. 2, p Macmillan Publishing Company, Inc., New York. 9. Mantel, N., and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22: National Committee for Clinical Laboratory Standards Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa. 11. Parish, L. C., D. M. Cocchetto, K. Werner, D. L. Jungkind, and J. Witkowski Cefuroxime in the treatment of cutaneous infections. Int. J. Dermatol. 26: Powell, D. A., N. C. James, M. Ossi, M. C. Nahata, and K. H. Donn Pharmacokinetics of cefuroxime suspension in infants and children. Antimicrob. Agents Chemother. 35: van Elteren, P. H On the combination of independent two-sample tests of Wilcoxon. Bull. Int. Stat. Inst. 37: Watts, H. F., A. H. Williams, and D. M. Cox A pilot study of cefuroxime (Zinnat) and Augmentin in the treatment of skin and soft tissue infections in general practice. Clin. Trials J. 24:
PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy design: The study was a multicentre, prospective, randomised, doubleblind, parallel-group study.
2 11 September 1.997 Page 9 of161 SYNOPSIS FUT 9403 INT : FUCIDIN VERSUS ERYTHROMYCIN IN SKIN AND SOFT TISSUE INFECTION. A comparison of sodium fusidate tablets 250mg bd (Fucidin tablets) and erythromycin
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationL. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 125-131 A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More informationFusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P
Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P Record Status This is a critical abstract of an economic evaluation that meets
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationTOUGH ON IMPETIGO GENTLE ON THE1 PATIENT. Demonstrated efficacy and safety1. New treatment option now available!
New treatment option now available! TOUGH ON IMPETIGO GENTLE ON THE1 PATIENT Demonstrated efficacy and safety1 Home Efficacy Safety Convenience (ozenoxacin) is indicated for the topical treatment of impetigo
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationComparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM)
Special Article Comparative Efficacy and Safety Evaluation of Cefaclor VS Amoxycillin + Clavulanate in Children with Acute Otitis Media (AOM) Mukesh Aggarwal, Ramanuj Sinha 1, M. Vasudeva Murali 2, Prita
More informationROSOBAC-1GM / ROSOBAC-FORT
ROSOBAC-1GM / ROSOBAC-FORT ROSOBAC - 1GM. COMPOSITION : Each vial contains Sterile Cefoperazone Sodium IP Eq. to Anhydrous Cefoperazone - Sterile Sulbactam Sodium USP Eq. to Anhydrous Sulbactam - ROSOBAC
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationoftioconazole Cream 1% versus
The Journal ofinternational Medical Research 1987; IS: 2~3l Comparative and Non-comparative Studies ofthe Efficacy and Tolerance oftioconazole Cream 1% versus Another Imidazole and/or Placebo in Neonates
More informationGROUP A STREPTOCOCCUS (GAS) INVASIVE
GROUP A STREPTOCOCCUS (GAS) INVASIVE Case definition CONFIRMED CASE Laboratory confirmation of infection with or without clinical evidence of invasive disease: isolation of group A streptococcus (Streptococcus
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w)
ALTARGO TM Retapamulin QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) PHARMACEUTICAL FORM Ointment. CLINICAL PARTICULARS Indications ALTARGO (retapamulin) 1% ointment is indicated
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationXerava (eravacycline) NEW PRODUCT SLIDESHOW
Xerava (eravacycline) NEW PRODUCT SLIDESHOW Introduction Brand name: Xerava Generic name: Eravacycline Pharmacological class: Tetracycline antibiotic Strength and Formulation: 50mg; per vial; lyophilized
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Fusidic Acid 2% Cream SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 % cream. Each gram contains 20 mg fusidic acid. Excipient(s) with
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationRochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH)
Rochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH) Clinical Practice Guideline* for the Diagnosis and Management of Acute Bacterial
More informationDrug Class Review on Macrolides
Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationPhenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva
Journal of Antimicrobial Chemotherapy (1996) 7, 1-18 Phexymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva R. S.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAerobic gram-positive microorganisms Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes
AZIMEX Composition Each 5 ml contains Azithromycin (as dihydrate) 200 mg Powder Action Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfering with
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules & Powder Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Azimex
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationTHE USE OF THE PENICILLINASE-RESISTANT
Therapeutic problems THE USE OF THE PENICILLINASE-RESISTANT PENICILLIN IN THE PNEUMONIAS OF CHILDREN MARTHA D. Yow, MARY A. SOUTH AND CHARLES G. HESS From the Department of Pediatrics, Baylor University
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationReceived 25 November 2002/Returned for modification 14 February 2003/Accepted 11 April 2003
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2003, p. 2770 2774 Vol. 47, No. 9 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.9.2770 2774.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Henry A. McKinnell, Jr., Ph.D. Chairman of the Board and Chief Executive
More informationReference ID: single. Uncomplicated gonorrhea
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CEFTIN safely and effectively. See full prescribing information for CEFTIN. CEFTIN (cefuroxime axetil)
More informationAnnex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications
Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationCefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1998, p. 729 733 Vol. 42, No. 4 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Cefepime versus Ceftriaxone for Empiric Treatment of
More informationImpavido. (miltefosine) New Product Slideshow
Impavido (miltefosine) New Product Slideshow Introduction Brand name: Impavido Generic name: Miltefosine Pharmacological class: Antileishmanial agent Strength and Formulation: 50mg; hard gel capsules Manufacturer:
More informationBeta-lactamase production should have no effect on Azithromycin activity.
AZIMEX Composition Azimex 250 Capsules Each capsule contains Azithromycin (as dihydrate) 250 mg Capsules Azimex 500 mg Capsules Each capsule contains Azithromycin (as dihydrate) 500 mg Action Azithromycin
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationChoosing an appropriate antimicrobial agent. 3) the spectrum of potential pathogens
Choosing an appropriate antimicrobial agent Consider: 1) the host 2) the site of infection 3) the spectrum of potential pathogens 4) the likelihood that these pathogens are resistant to antimicrobial agents
More informationA comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever
Original article A comparative trial of Azithromycin versus Doxycycline for the treatment in Rickettsial Fever Dr Deo Bhushan, Dr Jadhav Jayashree, DR Nigavekar P V, DR Himanshu Kumar Department of Pediatrics,
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationNOVACEF Tablets (Cefuroxime axetil)
Published on: 6 Oct 2016 NOVACEF Tablets (Cefuroxime axetil) Composition NOVACEF 250 Tablets Each film-coated tablet contains: Cefuroxime Axetil, IP, equivalent to Cefuroxime. 250 mg NOVACEF 500 Tablets
More informationPage 1 of 21. Adult Patients and Pediatric Patients Dosage Guidelines for Cefuroxime Axetil Tablets USP. Infection
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cefuroxime Axetil Tablets USP safely and effectively. See full prescribing information for Cefuroxime
More informationEffectiveness of Short-Course Therapy (5 Days) with Cefuroxime Axetil in Treatment of Secondary Bacterial Infections of Acute Bronchitis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1995, p. 2528 2534 Vol. 39, No. 11 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Effectiveness of Short-Course Therapy (5 Days) with
More informationALTARGO. Retapamulin. Retapamulin 10 mg per gram (1% w/w)
ALTARGO Retapamulin 1. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) 2. PHARMACEUTICAL FORM Ointment 3. CLINICAL PARTICULARS 3.1 Indications Retapamulin is indicated for
More informationAciphin Ceftriaxone Sodium
Aciphin Ceftriaxone Sodium Only for the use of Medical Professionals Description Aciphin is a bactericidal, long-acting, broad spectrum, parenteral cephalosporin preparation, active against a wide range
More informationOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
doi: 10.1111/j.1742-1241.2008.01824.x ORIGINAL PAPER Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry W. J. Martone, K. C. Lindfield, D. E. Katz OnlineOpen: This
More information090177e182b31c5d\0.1\Draft\Versioned On:16-Dec :12
MAH: / Product: IBU/PSE Protocol Number EudraCT number (if applicable) Trial report number PMID / D.O.I. (if applicable) Date of trial Is the trial Trial design Background for conducting the trial Participants
More informationClinico-etiological study of pyodermas in a tertiary care hospital
Original Research Article Purnachandra Badabagni 1, Shashikant Malkud 2,* 1 Associate Professor, 2 Assistant Professor, Dept. of Dermatology, Venereology and Leprosy, MNR Medical College & Hospital, Sangareddy,
More informationStudy on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward
HK J Paediatr (new series) 2002;7:33-38 Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward CM HUI, K TSE Abstract Objective: To estimate the incidence rate and risk factors
More informationRx only. Chemically, hydroxyethyl
CEFUROXIME AXETIL TABLETS USP Rx only PRESCRIBING INFORMATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationPRESCRIBING INFORMATION. Cloxacillin for Injection. Cloxacillin Powder for Solution (as cloxacillin sodium) 500mg powder/vial.
PRESCRIBING INFORMATION Pr Cloxacillin for Injection Cloxacillin Powder for Solution (as cloxacillin sodium) 500mg powder/vial 1g powder/vial 2g powder/vial 10g powder/vial STERILE Antibiotic SteriMax
More informationUncomplicated skin and skin-structure 250 or 500 mg every hours Uncomplicated urinary tract infections 250 mg every 12 7 to 10
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CEFTIN safely and effectively. See full prescribing information for CEFTIN. CEFTIN (cefuroxime axetil)
More informationCeftizoxime in the treatment of infections in patients with cancer
Journal of Antimicrobial Chemotherapy (98), Suppl. C, 67-73 Ceftizoxime in the treatment of infections in patients with cancer V. Fainstein, R. Bolivar,. Elting, M. Valdivieso and G. P. Bodey Department
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationUrinary Tract Infections and Their Effects on the Urogenital and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1986, p. 107-111 Vol. 29, No. 1-0066-4804/86/010107-05$02.00/0 Copyright 1986, American Society for Microbiology Amoxicillin-Clavulanic Acid Versus Cefaclor
More informationANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN
MARCH 2016 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.
More informationSUCRALFATE ISELPIN 1 g Tablet
1.0 PHARMACOLOGIC CATEGORY CYTOPROTECTOR 2.0 DESCRIPTION SUCRALFATE ISELPIN 1 g Tablet Sucralfate is a white, amorphous powder which is soluble in strong acids and in alkalis but practically insoluble
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationDOSAGE FORMS AND STRENGTHS Cream: Each gram contains 10 mg of ozenoxacin (1%) (3).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XEPI TM safely and effectively. See full prescribing information for XEPI TM. XEPI TM (ozenoxacin)
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Rapenin (phenoxymethylpenicillin potassium) is indicated for the treatment of infections caused by penicillin-sensitive bacteria.
More informationMRSA: A TEAM APPROACH
Eric Bosley, MD Laura Stadler, MD John MD J h Draus, D MRSA: A TEAM APPROACH PART I: OUTPATIENT ISSUES AND MANAGEMENT NOT REQUIRING I&D OR HOSPITALIZATION Eric L. Bosley, MD, FAAP Pediatric Associates,
More informationPRESCRIBING INFORMATION. Cloxacillin Powder for Solution (as cloxacillin sodium) 500mg powder/vial. 1g powder/vial. 2g powder/vial.
PRESCRIBING INFORMATION Pr Cloxacillin for Injection Cloxacillin Powder for Solution (as cloxacillin sodium) 500mg powder/vial 1g powder/vial 2g powder/vial 10g powder/vial STERILE Antibiotic SteriMax
More informationZinplava. (bezlotoxumab) New Product Slideshow
Zinplava (bezlotoxumab) New Product Slideshow Introduction Brand name: Zinplava Generic name: Bezlotoxumab Pharmacological class: Human IgG1 monoclonal antibody Strength and Formulation: 25mg/mL; solution
More informationAppropriate Use of Antibiotics for the Treatment of Acute Upper Respiratory Tract Infections in Adults
Appropriate Use of Antibiotics for the Treatment of Acute Upper Respiratory Tract Infections in Adults Kyong Ran Peck, M.D. Division of Infectious Diseases Sungkyunkwan University School of Medicine, Samsung
More informationComparison of Cefuroxime Axetil and Doxycycline in Treatment of Patients with Early Lyme Disease Associated with Erythema Migrans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1995, p. 661 667 Vol. 39, No. 3 0066-4804/95/$04.00 0 Copyright 1995, American Society for Microbiology Comparison of Cefuroxime Axetil and in Treatment of Patients
More informationNifuroxazide (Ercefuryl) Plus Oral rehydration solution Versus Oral Rehydration Alone in Hospitalized Pediatric Gastroenteritis
Nifuroxazide (Ercefuryl) Plus Oral rehydration solution Versus Oral Rehydration Alone in Hospitalized Pediatric Gastroenteritis Lourdes T. Santiago, M.D.,* Catherine P. Ranoa, M.D.,** Edmond G. Chan, M.D.***
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationMANAGING ANTERIOR SEGMENT INFECTIONS IN CHILDREN
MANAGING ANTERIOR SEGMENT INFECTIONS IN CHILDREN Rachel A. Stacey Coulter, OD, MSEd, FAAO, Diplomate BVPPO Julie A. Tyler, OD, FAAO Nova Southeastern University College of Optometry, Fort Lauderdale, FL
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationVancomycin Orion , Version 1.0. Public Summary of the Risk Management Plan
Vancomycin Orion 18.6.2015, Version 1.0 Public Summary of the Risk Management Plan VI.2 Elements for a Public Summary Vancomycin Orion is intravenously administered glycopeptide antibiotic. It is indicated
More informationSequential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice
Journal of Antimicrobial Chemotherapy (987) 9, 385-39 equential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice Urs B. chaad, Jurg Pfenninger and Joanna Wedgwood-Krucko
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationSTUDY OF IMPETIGO AND THE RESISTANCE PATTERN OF THE ISOLATES TO VARIOUS ANTIBIOTICS
STUDY OF IMPETIGO AND THE RESISTANCE PATTERN OF THE ISOLATES TO VARIOUS ANTIBIOTICS Abstract Pages with reference to book, From 129 To 132 Aqeel Ahmad, Khursheed Ali Khan ( Department of Microbiology,
More informationCefadroxil for Oral Suspension USP 250 mg/5 ml and 500 mg/5 ml
Cefadroxil for Oral Suspension USP 250 mg/5 ml and 500 mg/5 ml Rx only To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil for oral suspension and other antibacterial
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationClinical Trial Synopsis
Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationSecondary efficacy endpoints for Part 2, the Eltrombopag-Only Period, included the proportion of subjects who
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information